These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 33476146)

  • 1. Structure- and Similarity-Based Survey of Allosteric Kinase Inhibitors, Activators, and Closely Related Compounds.
    Laufkötter O; Hu H; Miljković F; Bajorath J
    J Med Chem; 2022 Jan; 65(2):922-934. PubMed ID: 33476146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. αC helix displacement as a general approach for allosteric modulation of protein kinases.
    Palmieri L; Rastelli G
    Drug Discov Today; 2013 Apr; 18(7-8):407-14. PubMed ID: 23195331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic assessment of structure-promiscuity relationships between different types of kinase inhibitors.
    Hu H; Bajorath J
    Bioorg Med Chem; 2021 Jul; 41():116226. PubMed ID: 34082305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gaining Insights into Key Structural Hotspots within the Allosteric Binding Pockets of Protein Kinases.
    Bhujbal SP; Jun J; Park H; Moon J; Min K; Hah JM
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors.
    Vijayan RS; He P; Modi V; Duong-Ly KC; Ma H; Peterson JR; Dunbrack RL; Levy RM
    J Med Chem; 2015 Jan; 58(1):466-79. PubMed ID: 25478866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approach in Improving Potency and Selectivity of Kinase Inhibitors: Allosteric Kinase Inhibitors.
    Wei S; Zhao T; Wang J; Zhai X
    Mini Rev Med Chem; 2021; 21(8):991-1003. PubMed ID: 33355051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leveraging Structural Diversity and Allosteric Regulatory Mechanisms of Protein Kinases in the Discovery of Small Molecule Inhibitors.
    Verkhivker GM
    Curr Med Chem; 2017; 24(42):4838-4872. PubMed ID: 27719654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DFGmodel: predicting protein kinase structures in inactive states for structure-based discovery of type-II inhibitors.
    Ung PM; Schlessinger A
    ACS Chem Biol; 2015 Jan; 10(1):269-78. PubMed ID: 25420233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allosteric modulation of a human protein kinase with monobodies.
    Zorba A; Nguyen V; Koide A; Hoemberger M; Zheng Y; Kutter S; Kim C; Koide S; Kern D
    Proc Natl Acad Sci U S A; 2019 Jul; 116(28):13937-13942. PubMed ID: 31239342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinase Atlas: Druggability Analysis of Potential Allosteric Sites in Kinases.
    Yueh C; Rettenmaier J; Xia B; Hall DR; Alekseenko A; Porter KA; Barkovich K; Keseru G; Whitty A; Wells JA; Vajda S; Kozakov D
    J Med Chem; 2019 Jul; 62(14):6512-6524. PubMed ID: 31274316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies for the selective regulation of kinases with allosteric modulators: exploiting exclusive structural features.
    Fang Z; Grütter C; Rauh D
    ACS Chem Biol; 2013 Jan; 8(1):58-70. PubMed ID: 23249378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pocketome of human kinases: prioritizing the ATP binding sites of (yet) untapped protein kinases for drug discovery.
    Volkamer A; Eid S; Turk S; Jaeger S; Rippmann F; Fulle S
    J Chem Inf Model; 2015 Mar; 55(3):538-49. PubMed ID: 25557645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases.
    Cowan-Jacob SW; Jahnke W; Knapp S
    Future Med Chem; 2014 Apr; 6(5):541-61. PubMed ID: 24649957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allosteric inhibition of Aurora-A kinase by a synthetic vNAR domain.
    Burgess SG; Oleksy A; Cavazza T; Richards MW; Vernos I; Matthews D; Bayliss R
    Open Biol; 2016 Jul; 6(7):. PubMed ID: 27411893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ins and outs of selective kinase inhibitor development.
    Müller S; Chaikuad A; Gray NS; Knapp S
    Nat Chem Biol; 2015 Nov; 11(11):818-21. PubMed ID: 26485069
    [No Abstract]   [Full Text] [Related]  

  • 16. Discovery and characterization of novel allosteric FAK inhibitors.
    Iwatani M; Iwata H; Okabe A; Skene RJ; Tomita N; Hayashi Y; Aramaki Y; Hosfield DJ; Hori A; Baba A; Miki H
    Eur J Med Chem; 2013 Mar; 61():49-60. PubMed ID: 22819505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein kinase inhibitors: structural insights into selectivity.
    Thaimattam R; Banerjee R; Miglani R; Iqbal J
    Curr Pharm Des; 2007; 13(27):2751-65. PubMed ID: 17897021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for the NMR-based identification and optimization of allosteric protein kinase inhibitors.
    Jahnke W; Blommers MJ; Fernández C; Zwingelstein C; Amstutz R
    Chembiochem; 2005 Sep; 6(9):1607-10. PubMed ID: 16028302
    [No Abstract]   [Full Text] [Related]  

  • 19. Allosteric Small-Molecule Serine/Threonine Kinase Inhibitors.
    Panicker RC; Chattopadhaya S; Coyne AG; Srinivasan R
    Adv Exp Med Biol; 2019; 1163():253-278. PubMed ID: 31707707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unexpected off-targets and paradoxical pathway activation by kinase inhibitors.
    Hantschel O
    ACS Chem Biol; 2015 Jan; 10(1):234-45. PubMed ID: 25531586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.